M-M-RII (measles, mumps, and rubella virus vaccine live) / Merck (MSD) - LARVOL DELTA

Adult immunization. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis B • Herpes Zoster • Infectious Disease • Inflammation • Influenza • Measles • Meningococcal Infections • Pertussis • Pneumococcal Infections • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tetanus • Varicella Zoster

Comparison chart: Some vaccines for adults. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis B • Infectious Disease • Inflammation • Influenza • Measles • Meningococcal Infections • Pertussis • Pneumococcal Infections • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tetanus

Latent variables in cognitive decline: introducing a behavioral-relational factor. (PubMed, J Clin Exp Neuropsychol) - "This current study findings emphasize the importance of assessing cognitive performance from a whole-person perspective. Future research should focus on using these factors to predict dementia-related outcomes (e.g. nursing home placement, progression of decline)."

Journal • Alzheimer's Disease • CNS Disorders • Dementia • Depression • Geriatric Disorders • Psychiatry

Computational fluid structure interaction analysis between aqueous humor and corneal shell. (PubMed, Proc Inst Mech Eng H) - "This FSI paradigm confirms flow-induced shear as a significant, spatially altering mechanical input in the anterior chamber, furthering the pressure-centric IOP attitude. The model provides quantitative organization for patient-specific glaucomatous pathology and surgical planning investigations."

Journal • CNS Disorders • Glaucoma • Ophthalmology

Proteomic profiling of olfactory exfoliates from people with subjective cognitive complaints reveal networks of olfactory biomarkers of cognitive performance. (PubMed, Front Aging Neurosci) - "This study demonstrates the feasibility of using OM-derived proteomics to identify molecular signatures associated with cognitive performance and highlights the OM as a potential site for non-invasive biomarker discovery. These findings provide a foundation for future studies integrating OM profiling with established AD biomarkers."

Biomarker • Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Frontotemporal Lobar Degeneration • MFN2 • NGFR • PLOD1

Enhanced sensitivity to plasma p-tau217 with proper names recall in the preclinical Alzheimer's cognitive composite. (PubMed, Brain Commun) - "Our findings position proper name-enhanced PACC as a clinically practical tool for tracking longitudinal cognitive trajectories, highlighting proper names delayed recall as a sensitive marker due to AD-type brain changes. Future work will validate its utility for trial enrichment and clinical screening."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Dementia

Measles serostatus among health care workers in a university clinic in Hungary in 2024. (PubMed, Prev Med Rep) - "Newer combinations, such as MMR-II/Priorix, elicited higher antibody levels compared to old combinations...A substantial proportion of HCWs have low level of measles antibodies, especially in specific age cohorts. Targeted screening and revaccination are recommended to close immunity gaps and prevent nosocomial transmission."

Journal • Infectious Disease • Measles

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=2360 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting | Trial completion date: May 2027 ➔ Oct 2027 | Trial primary completion date: May 2027 ➔ Oct 2027

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

Dose-specific childhood vaccine refusal in Balıkesir, Türkiye (2024): a population-based surveillance analysis. (PubMed, Turk J Pediatr) - "Mandatory documentation exposed substantial under-ascertainment of parental refusal in performance-based records. Refusal is disproportionately clustered at booster and later-childhood visits, with MMR-II approaching herd-immunity margins. Programmatically, pediatric booster encounters are key leverage points for targeted counseling, and sustained, transparent surveillance as enabled by the new policy, is essential for early signal detection and response."

Journal • Infectious Disease • Measles • Mumps • Novel Coronavirus Disease • Pediatrics • Rubella

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=1714 | Active, not recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Pneumococcal Infections

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Pneumococcal Infections

CORAL: Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (clinicaltrials.gov) - P3 | N=2226 | Terminated | Sponsor: Sanofi Pasteur, a Sanofi Company | Active, not recruiting ➔ Terminated; Sponsor decision

Trial termination • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (clinicaltrials.gov) - P3 | N=896 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (clinicaltrials.gov) - P3 | N=896 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

Drug Development. (PubMed, Alzheimers Dement) - "Our analysis demonstrated the utility of confirmatory scales to screen fail subjects lacking objectifiable cognitive decline. Depending on the instrument used, between a quarter and a third of subjects were deemed not eligible. However, substantial differences in performance between the instruments used were identified, especially in potential study participants with MMSE scores of 26 or below. While the FCSRT and WMS-LMII performed in an almost linear manner over the tested MMSE range, the RBANS performed in a curvilinear manner. Additionally, for those with MMSE scores below 25, the RBANS only identified a small subset of subjects as ineligible. Those weighing implementation of these instruments in a clinical trial should consider the presented data in the context of the MMSE inclusion criteria, subject and rater burden, and the goals of the trial."

Journal • Alzheimer's Disease • CNS Disorders

Biomarkers. (PubMed, Alzheimers Dement) - "Remarkably, substituting proper name delayed recall for logical memory total score improves sensitivity for tracking longitudinal cognitive decline related to AD blood-biomarker p-Tau217 group. Our study highlights a novel language measure that yielded composites more sensitive to AD-related preclinical changes. Follow-up analyses will investigate implications for screening and clinical trials."

Biomarker • Journal • Alzheimer's Disease • CNS Disorders • Dementia

Safety of live-attenuated MMR vaccination in patients with multiple myeloma receiving daratumumab after autologous stem cell transplantation (ASH 2025) - "The majority of patients (59%) received daratumumabin combination with lenalidomide (52%) or pomalidomide (7%) and dexamethasone, with remainingpatients receiving in combination with a proteasome inhibitor (7%) or as monotherapy (34%)...Our findings suggest MMR vaccination in immunocompromised patients with myeloma receivingdaratumumab after ASCT appears to be safe. Though a limited sample size, we did not observe anyvaccine-related disseminated measles, mumps, or rubella infections post-vaccination. MMR vaccination isespecially important for these immunocompromised patients given the rising rates of vaccine hesitancyin the general population and the increase in confirmed measles cases in the United States during 2024and 2025."

Clinical • Dermatology • Hematological Malignancies • Infectious Disease • Measles • Multiple Myeloma • Mumps • Musculoskeletal Pain • Otorhinolaryngology • Respiratory Diseases • Rubella • Sinusitis • Transplantation

A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population (clinicaltrials.gov) - P3 | N=2440 | Recruiting | Sponsor: Sanofi | Trial completion date: Oct 2029 ➔ Mar 2030

Trial completion date • Pediatrics

Plasma phosphorylated tau-217 correlates with brain atrophy, cognition, and cerebrospinal fluid biomarkers in a cognitively healthy community cohort. (PubMed, Brain Commun) - "All plasma biomarkers correlated significantly with their CSF counterpart. These findings reinforce the utility of plasma biomarkers, particularly pTau-217, as indicators of neurodegenerative processes, even in asymptomatic individuals."

Biomarker • Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Dementia • Diabetes • Dyslipidemia • Hypertension • Inflammation • Metabolic Disorders • Aβ42 • GFAP • NEFL

Advances in Proximity-Assisted Bioconjugation. (PubMed, Acc Chem Res) - "Here, we discovered the secondary participation of proximal lysines on Trastuzumab-V205C and Gemtuzumab-V205C, conjugatable THIOMAB antibodies commonly used in ADCs, leading to the formation of distinct bioconjugate products relative to IgGs without such lysines...In short, this Account highlights our group's contributions to and insights on PAB methodologies wherein we illustrate how PIC can be thoughtfully applied to bioconjugation techniques for various aims including regioselective bioconjugation and enhanced bioconjugate stability. We expect that PAB approaches will continue to diversify bioconjugation applications and greatly expand the toolkit of chemical biologists."

Journal

A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population (clinicaltrials.gov) - P3 | N=2440 | Recruiting | Sponsor: Sanofi

New P3 trial • Pediatrics

Cognitive Outcomes and Quality of Life in Stable Renal Transplant Patients Switched from Twice-Daily Tacrolimus to Envarsus XRTM (WTC 2025) - "Kidney transplant patients converted from IR tacrolimus to LCP-Tacro led to statistically significant benefits in cognitive function including visual attention, executive functioning, and memory."

Clinical • HEOR • Late-breaking abstract • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Insomnia • Movement Disorders • Post-traumatic Stress Disorder • Sleep Disorder • Solid Tumor • Transplantation

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Recruiting | Sponsor: Sanofi | Trial completion date: May 2027 ➔ Aug 2027 | Trial primary completion date: May 2027 ➔ Aug 2027

Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

In brief: Prevention of measles. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Infectious Disease • Measles

Network localization of regional homogeneity alterations in Parkinson's disease. (PubMed, Front Aging Neurosci) - "This network-centric view offers a unifying perspective on PD pathophysiology, highlighting large-scale systems disruption and potentially reconciling previous localization inconsistencies. This approach underscores the value of network neuroscience for understanding PD mechanisms."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease